UroGen Pharma Ltd. — Director's Dealing 2024

Feb 12, 2024

SEC Form 4/A — Form 4/A

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2024-01-31

Reporting Person: Kim Dong (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-31	Ordinary Shares	M	3333	—	Acquired	35253	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F2: This amendment corrects and restates the Amount of Securities Beneficially Owned Following Reported Transaction reported in the original Form 4 filed on February 2, 2024.